

Scrooge and intellectual property rights

BMJ: British Medical Journal

333, 1279-1280

DOI: [10.1136/bmj.39048.428380.80](https://doi.org/10.1136/bmj.39048.428380.80)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Will longer antimicrobial patents improve global public health?. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 559-566. | 9.1 | 54 |
| 2 | Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthritis. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 4. | 1.9 | 49 |
| 3 | Stimulating revolutionary science with mega-cash prizes. <i>Medical Hypotheses</i> , 2008, 70, 709-713. | 1.5 | 2 |
| 5 | Three Proposals for Rewarding Novel Health Technologies Benefiting People Living in Poverty. A Comparative Analysis of Prize Funds, Health Impact Funds and a Cost-Effectiveness/Competitive Tender Treaty. <i>Public Health Ethics</i> , 2008, 1, 146-153. | 1.0 | 13 |
| 6 | Excluding the Poor from Accessing Biomedical Literature: A Rights Violation That Impedes Global Health. <i>Health and Human Rights</i> , 2008, 10, 21. | 1.3 | 16 |
| 7 | Innovation and Technology Transfer to Address Climate Change: Lessons from the Global Debate on Intellectual Property and Public Health. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 9 |
| 8 | Researchers ponder a patent-free world. <i>Nature Medicine</i> , 2009, 15, 1240-1241. | 30.7 | 2 |
| 9 | Extending private-€collective innovation: a case study. <i>R and D Management</i> , 2009, 39, 170-191. | 5.3 | 84 |
| 10 | Considering the economic principles of pharmaceutical R&D. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 21-22. | 5.0 | 0 |
| 11 | A review of intellectual property rights in biotechnology. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2009, 7, 228-231. | 1.8 | 5 |
| 12 | How should we support pharmaceutical innovation?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 313-320. | 1.4 | 5 |
| 13 | In favour of a Millian proposal to reform biomedical research. <i>Synthese</i> , 2010, 177, 427-447. | 1.1 | 23 |
| 14 | One step forward, one step sideways? Expanding research capacity for neglected diseases. <i>BMC International Health and Human Rights</i> , 2010, 10, 20. | 2.5 | 15 |
| 15 | Patents and Pharmaceutical R&D: Consolidating Private-Public Partnership Approach to Global Public Health Crises. <i>Journal of World Intellectual Property</i> , 2010, 13, 556. | 0.6 | 14 |
| 16 | Ethical Issues Surrounding Intellectual Property Rights. <i>Philosophy Compass</i> , 2010, 5, 1107-1115. | 1.3 | 9 |
| 17 | A theoretical flaw in the advance market commitment idea. <i>Journal of Medical Ethics</i> , 2010, 36, 339-343. | 1.8 | 3 |
| 18 | Medicine for Tomorrow: Some Alternative Proposals to Promote Socially Beneficial Research and Development in Pharmaceuticals. <i>Journal of Generic Medicines</i> , 2010, 7, 217-226. | 0.2 | 41 |
| 19 | Advance Monopoly Commitment?. <i>Public Health Ethics</i> , 2011, 4, 297-302. | 1.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 20 | Global Governance and Human Development: Promoting Democratic Accountability and Institutional Experimentation. <i>Journal of Human Development and Capabilities</i> , 2011, 12, 469-491. | 2.0 | 5 |
| 21 | Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage * *This chapter is based upon material in R.A. Bouchard, J. Sawani, C. McLelland, M. Sawicka, and R. Hawkins, "The Pas de Deux of Pharmaceutical Regulation and Innovation: Who's Leading Whom?" <i>Berkeley Technology Law Journal</i> 24(3): 1461-522 (2009)... 2012... 103-145. | | 0 |
| 22 | Pharmaceutical companies and access to medicines " social integration and ethical CSR resolution of a global public choice problem. <i>Journal of Global Ethics</i> , 2012, 8, 139-167. | 0.5 | 9 |
| 23 | Biomarker patents for diagnostics: problem or solution?. <i>Nature Biotechnology</i> , 2012, 30, 498-500. | 17.5 | 11 |
| 24 | It's About Scientific Secrecy, Dummy: A Better Equilibrium Among Genomics Patenting, Scientific Research and Health Care. <i>Science and Engineering Ethics</i> , 2012, 18, 263-284. | 2.9 | 1 |
| 25 | Ethics in Biomedical Research and Practice. <i>History, Philosophy and Theory of the Life Sciences</i> , 2013, , 705-722. | 0.4 | 0 |
| 26 | Technology and intellectual property strategy of a firm: A view through the commons theory lens. <i>IIMB Management Review</i> , 2013, 25, 213-227. | 1.4 | 3 |
| 27 | A consumer adoption model for personalized medicine: an exploratory study. <i>International Journal of Pharmaceutical and Healthcare Marketing</i> , 2014, 8, 371-391. | 1.3 | 4 |
| 28 | Inventing Prizes: A Historical Perspective on Innovation Awards and Technology Policy. <i>Business History Review</i> , 2015, 89, 631-660. | 0.4 | 25 |
| 29 | Patent Funded Access to Medicines. <i>Developing World Bioethics</i> , 2015, 15, 152-161. | 0.9 | 1 |
| 30 | The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation. <i>Health Affairs</i> , 2015, 34, 302-310. | 5.2 | 50 |
| 31 | Intellectual Property and Innovation in Translational Medicine. , 2015, , 281-297. | | 2 |
| 32 | Direct-to-Consumer Advertising. , 2016, , 267-279. | | 0 |
| 33 | Patents and Progress. <i>Perspectives on Science</i> , 2016, 24, 505-528. | 1.0 | 5 |
| 35 | Governing pharmaceutical innovations in Africa: Inclusive models for accelerating access to quality medicines. <i>Cogent Medicine</i> , 2018, 5, 1500196. | 0.7 | 9 |
| 36 | Politics of Intellectual Property Rights (IPRs) in Medicine: The Dichotomies. <i>FIIB Business Review</i> , 2018, 7, 69-79. | 3.1 | 0 |
| 37 | A Fair IP Landscape. , 2019, , 149-190. | | 0 |
| 38 | Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective. <i>Global Policy</i> , 2020, 11, 46-55. | 1.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 39 | Inclusive Biomedical Innovation during the COVID-19 Pandemic. <i>Global Policy</i> , 2020, 11, 647-649. | 1.7 | 3 |
| 40 | Financing Drug Innovation in the US: Current Framework and Emerging Challenges. <i>Pharmacoeconomics</i> , 2020, 38, 905-911. | 3.3 | 1 |
| 41 | Intellectual property and innovation in translational medicine. , 2021, , 389-411. | | 0 |
| 42 | Bioprospecting Insights. <i>Topics in Biodiversity and Conservation</i> , 2017, , 299-303. | 1.0 | 1 |
| 44 | Historical Perspectives on Patent Systems in Economic Development. , 2008, , 215-244. | | 5 |
| 45 | Intellectual Property Rights And The TRIPS Agreement : An Overview Of Ethical Problems And Some Proposed Solutions. <i>Policy Research Working Papers</i> , 2010, , . | 1.4 | 5 |
| 46 | Personal Health Information in the Age of Ubiquitous Health. , 2010, , 166-189. | | 0 |
| 48 | Fire " Chronic Viral Infection and Cancer. , 2013, , 357-399. | | 0 |
| 49 | How (Not) to Reform Biomedical Research: A Review of Some Policy Proposals. , 2014, , 97-110. | | 0 |
| 50 | Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 1 |
| 51 | Challenges of the Knowledge Based Economy in East Asia. <i>Information Management and Business Review</i> , 2016, 8, 36-49. | 0.1 | 0 |
| 52 | Regional Health Care, Education, International Trade, Other Services and Household Consumption. <i>Advances in Applied General Equilibrium Modeling</i> , 2017, , 83-97. | 0.4 | 0 |